B+
Bull case
25%
Probability
Target price
$18.80
Analysis reference price unavailable
Analysis 2026-10-10 · RankAlpha Sentiment Codex
SGRY
Surgery PartnersDNasdaq / Health Care Equipment & Services
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
50%
Probability
Target price
$15.50
Analysis reference price unavailable
Analysis 2026-10-10 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$10.50
Analysis reference price unavailable
Analysis 2026-10-10 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-10-10
Recent news sentiment (30D)
-26.0
Negative
Company
-
Unavailable
Macro
-26.0
Negative
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+18.9
Score
AI commentary
The sale supports a cautiously positive monitoring view, but the supplied anchor does not establish a verified post-sale price reaction. News coverage is thin; analyst revisions, options skew, short interest, employee sentiment, and sufficient social readings were unavailable. Zero sentiment fields mean unavailable data, not neutral measurements. The September 23 StockStory article is third-party opinion, not a company release. [#8-K-2026-09-17] [#SEC-8K-2026-08-10]
RankAlpha Sentiment Codex - 2026-10-10
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-12-31eventDebt reduction after completed Idaho Falls saleHigh impact
The Idaho Falls hospital disposition closed September 14 for approximately $796.6 million, subject to adjustments. Management intends to use the proceeds primarily to repay debt. The next test is actual repayment and resulting leverage; December 31 is an assessment horizon, not an announced milestone. [#8-K-2026-09-17]
2026-12-31catalystPost-sale outlook clarificationHigh impact
Q2 guidance of $3.35–$3.45 billion in 2026 revenue and at least $530 million in adjusted EBITDA excluded the then-pending divestiture. A post-sale outlook and reported debt balance would clarify the continuing business; December 31 is a monitoring horizon, not a confirmed report date. [#SEC-8K-2026-08-10] [#8-K-2026-09-17]
2027-09-30catalystCase growth and cash conversionHigh impact
Q2 same-facility revenue grew 5.0%, largely through 4.8% higher revenue per case; cases rose only 0.3%. Adjusted EBITDA and operating cash flow declined year over year. Sustained case growth and better cash conversion would strengthen the thesis; the date is an assessment horizon. [#SEC-8K-2026-08-10]
Recommendation
N/A
No formal recommendation provided.
As of 2026-10-10 • Updated nightlySource: Internal modelMethodology